Davunetide vs N-Acetyl Selank

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Tuftsin-derived heptapeptide with structural modifications that resist enzymatic degradation. Modulates GABA-A receptor complex, increases enkephalin levels in limbic system, and influences serotonin metabolism.

N-Acetyl-Selank is an acetylated derivative of selank (TKPRPGP), a synthetic heptapeptide anxiolytic developed from a tuftsin-based sequence; N-acetylation at the N-terminus is proposed to improve resistance to enzymatic degradation and potentially alter blood-brain barrier permeability relative to the parent compound, with the expectation of enhanced CNS bioavailability and duration of action. The pharmacological rationale derives from the parent compound selank, which acts through GABAergic, serotonergic, and enkephalinergic pathways to produce anxiolytic and nootropic effects in preclinical models and limited Russian human clinical studies; N-acetyl-selank is presumed to retain similar receptor interactions with modified pharmacokinetics. No publications indexed in PubMed specifically examine N-acetyl-selank as a distinct compound; no human clinical trials, independent preclinical studies, or pharmacokinetic comparisons with the parent selank exist in the indexed scientific literature, representing a complete absence of specific evidence for this analog beyond its structural modification. N-Acetyl-Selank has no FDA approval and no approved indication in any jurisdiction; it is available through research chemical suppliers as a purported improvement on selank, but its pharmacological properties, safety profile, and clinical utility in humans are entirely uncharacterized as a distinct compound.